For comments, suggestions
Created with Raphaël 2.1.0 29.04.2015 Formal examination (assignment of filing date) 27.05.2015 Preliminary and substantive examination 31.03.2016 Publication of the decision of grant (B1) 30.09.2016 Completion of the opposition filing period 31.10.2016 Issuance of patent (C1) 29.04.2020 Valid until 31.10.2021 Publication of the decision of forfeiture, the term of re-establishment has expired

Patent lapsed


(11)Number of the document4407
(21)Number of the applicationa 2015 0041
(22)Filing date of the application2015.04.29
 Date of filing the request for examination (de fond) 29.04.2015
(71)Name(s) of applicant(s), code of the countryUNIVERSITATEA DE STAT DIN MOLDOVA, MD;
(72)Name(s) of inventor(s), code of the countryGULEA Aurelian, MD; GRAUR Vasilii, MD; TAPCOV Victor, MD;
(73)Name(s) of owner(s), code of the countryUNIVERSITATEA DE STAT DIN MOLDOVA, MD;
(54)Title of the inventionInhibitor of human myeloid leukemia HL-60 cells based on bis[N-(prop-2-en-1-yl)-2-(pyridine-2-ylmethylidene)hydrazinecarbothioamide]nickel(II) chloride hydrate
(13)Kind-of-document code
C1, BOPI 10/2016
B1, BOPI 03/2016
(51)International Patent Classification C07D 213/48 (2006.01); C07F 15/04 (2006.01); C07C 337/08 (2006.01); A61K 31/4402 (2006.01); A61P 35/02 (2006.01);
(19)CountryMD
(45)Date of publication of patent granting decision:2016.03.31
(47)Date of issuance of patent2016.10.31
 Substantive examiner(s)IUSTIN Viorel, GROSU Petru, JOVMIR Tudor
 Payment for maintenance up to the date2020.04.29
 Date of patent termination2020.04.29
 Date of publication of the termination of patent, with the right of restoration2020.10.31
 Date of publication of the termination of patent, without the right of restoration2021.10.31
Up
/inventions/Details.aspx?id=a+2015+0041